Therapeutic Advances in Psychopharmacology

Papers
(The TQCC of Therapeutic Advances in Psychopharmacology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Relationship between resilience and mental health among COVID-19 bereaved people: the mediating role of dual process coping78
Analysis of the clinical characteristics of olanzapine-induced acute pancreatitis44
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review41
Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital39
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness38
History repeating: guidelines to address common problems in psychedelic science38
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial34
The missing link? Pharmacists’ perspectives on discontinuation of long-term antidepressants: a qualitative study33
Disrupted emotion regulation and spontaneous neural activity in panic disorder: a resting-state fMRI study25
Comment on: History repeating: guidelines to address common problems in psychedelic science24
Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit23
Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’22
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study22
The efficacy of antipsychotics in the treatment of physical aggressive behavior in patients with dementia in nursing homes20
Reasons for discontinuing and restarting lithium multiple times: a case-register study based on the South London and Maudsley NHS Foundation Trust Clinical Record Interactive Search system19
Corrigendum to “Managing medical and psychiatric multimorbidity in older patients”19
Brugada syndrome: should we be screening patients before prescribing psychotropic medication?19
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry18
Reasons for admission to a general medical hospital for patients taking clozapine17
Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review15
Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia15
Clinical outcomes following switching antipsychotic treatment due to market withdrawal: a retrospective naturalistic cohort study of pipotiazine palmitate injection (Piportil Depot) discontinuation, s14
Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings?14
Risperidone-induced priapism: a case report and literature review14
Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey14
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand13
Impact of CYP1A , CYP2C19 , CYP2D6 , CYP3A4 , CYP3A5 13
Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors13
Risperidone-induced neuroleptic malignant syndrome: a case report13
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review13
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia12
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications12
Will psilocybin lose its magic in the clinical setting?12
Corrigendum to ‘Comment on: History repeating: guidelines to address common problems in psychedelic science’11
Anticholinergic action is rarely a good thing9
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies9
0.4451630115509